Failure at 12 months · participants with glaucoma surgery
It is very uncertain whether low‐dose postoperative 5‐Fluorouracil changes failure at 12 months compared with control (very low certainty).
1 finding from 1 review
Mean intraocular pressure · participants with glaucoma surgery
1 finding from 1 review
Complications ‐ wound leak · participants with glaucoma surgery
It is very uncertain whether low‐dose postoperative 5‐Fluorouracil changes complications ‐ wound leak compared with control (very low certainty).
1 finding from 1 review
Complications ‐ hypotonous maculopathy ‐ not reported · participants with glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
Complications ‐ shallow anterior chamber ‐ not reported · participants with glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
Complications ‐ wound leak · participants with glaucoma surgery
Regular‐dose postoperative 5‐Fluorouracil showed no clear difference in complications ‐ wound leak compared with control (low certainty).
1 finding from 1 review
Complications ‐ epithelial toxicity ‐ not reported · participants with glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
Failure at 12 months Need for repeat surgery or uncontrolled IOP (usually more than 22 mm Hg) despite additional topical or systemic medications · participants with glaucoma surgery
Intraoperative 5‐Fluorouracil leads to lower failure at 12 months Need for repeat surgery or uncontrolled IOP… compared with placebo or control (high certainty).
1 finding from 1 review
Mean intraocular pressure · participants with glaucoma surgery
1 finding from 1 review
Complications ‐ wound leak · participants with glaucoma surgery
Intraoperative 5‐Fluorouracil showed no clear difference in complications ‐ wound leak compared with placebo or control (high certainty).
1 finding from 1 review
Complications ‐ hypotonous maculopathy · participants with glaucoma surgery
Intraoperative 5‐Fluorouracil showed no clear difference in complications ‐ hypotonous maculopathy compared with placebo or control (moderate certainty).
1 finding from 1 review
Complications ‐ shallow anterior chamber · participants with glaucoma surgery
Intraoperative 5‐Fluorouracil leads to higher complications ‐ shallow anterior chamber compared with placebo or control (high certainty).
1 finding from 1 review
Complications ‐ epithelial toxicity · participants with glaucoma surgery
Intraoperative 5‐Fluorouracil showed no clear difference in complications ‐ epithelial toxicity compared with placebo or control (moderate certainty).
1 finding from 1 review
Complications ‐ hypotonous maculopathy · participants with glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
Complications ‐ shallow anterior chamber · participants with glaucoma surgery
Regular‐dose postoperative 5‐Fluorouracil showed no clear difference in complications ‐ shallow anterior chamber compared with control (low certainty).
1 finding from 1 review
Complications ‐ epithelial toxicity · participants with glaucoma surgery
Regular‐dose postoperative 5‐Fluorouracil may leads to higher complications ‐ epithelial toxicity compared with control (low certainty).
1 finding from 1 review
Failure at 12 months ‐ high risk of failure · participants with glaucoma surgery
Regular‐dose postoperative 5‐Fluorouracil probably leads to lower failure at 12 months ‐ high risk of failure compared with control (moderate certainty).
1 finding from 1 review
Complications ‐ wound leak ‐ high risk of failure · participants with glaucoma surgery
Regular‐dose postoperative 5‐Fluorouracil probably leads to higher complications ‐ wound leak ‐ high risk of failure compared with control (moderate certainty).
1 finding from 1 review
Intervention not reported
BCVA gain of 15 letters or more ( · participants with CRVO macular oedema of duration less than 9 months (mean < 3 months) and no prior treatment
The intervention leads to higher BCVA gain of 15 letters or more ( (high certainty).
1 finding from 1 review
Intervention not reported
BCVA loss of 15 letters or more ( · participants with CRVO macular oedema of duration less than 9 months (mean < 3 months) and no prior treatment
The intervention leads to lower BCVA loss of 15 letters or more ( (high certainty).
1 finding from 1 review